Sat, Aug 30, 2014, 9:53 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • rule4man7@gmail.com rule4man7 May 16, 2013 10:12 PM Flag

    300k per treatment every year or just one year?

    I need some help understand if this orphan drug must be administered only for one year or in perpetuity?
    I'm scratching my head figuring out how many Insurance companies will allow this for their subscribers knowing that insurers would like to pay for nothing if they can.

    Is it reasonable to expect the best case scenario that the CEO sees in every insurer willing to pay and the theoretical 3000 users getting on the bandwagon?

    Isn't this drug really for the ultra rich? Do you think insurers are willing to pay that much per year without eventually cancelling someone's insurance. Heck they can fight people in court and win by trying to bankrupt the patient with lawyer fees.
    We know we live in a greedy world and even the CEO acknowledged early this year that revenue this year will be limited to about 15-20 million( before the upward price revision) for 250-300 patients instead of up to 85 million if he can make them all pay full price from day one.

    Are people not thinking about these things? Who the hell is going to afford this drug? Insurers can go bankrupt supporting such patients never mind the absolute majority of patients who are not silver spoon fed to afford this treatment.

    What kind of euphoria has swept over Wall Street for the 3rd time in the last 13 years?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • system_architect_enterprise system_architect_enterprise May 16, 2013 10:37 PM Flag

      $300K per year. Many insurance companies have already agreed to insure/cover the treatments. The insurance companies worked with AEGR in establishing the pricing, so they were involved from the beginning. Since so few patients need the medication, it is a very small overall amount per insurance company.

      Not at all a drug for the rich, in fact, your argument about bankrupting patients reveal your intent - maybe you are a short seller, or maybe just against this stock (I personally think you are a short). The company has a program for people that don't have insurance to offer them greatly reduced medicine in conjunction with some charities who will cover the reduced cost (this was a recommendation from the insurance companies). So all is well, they have it all worked out even if you didn't know about it Adam.

      • 1 Reply to system_architect_enterprise
      • rule4man7@gmail.com rule4man7 May 16, 2013 11:22 PM Flag

        good answer. Do you work for the company by any chance? the only question how realistic is their market since this is one of the worst countries in the industrialized world at treating patients. What are the risks of being on this drug continuously Vs the rewards? The outrageous cost might become secondary if patients start deteriorating or exhibiting adverse effects. Do you have answers for these questions or just target prices and btw what's your core switch speed sys architect?

 
AEGR
30.55-0.09(-0.29%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Synaptics Inc.
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT
Burger King Worldwide, Inc.
NYSEFri, Aug 29, 2014 4:02 PM EDT